The Threat of Pandemic Influenza Are We Ready? Workshop Summary (2005) / Chapter Skim
Currently Skimming:
Appendix C: The Critical Path to New Medical Products
Appendix C: The Critical Path to New Medical Products
Pages 388-389
The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.
From page 388... ...
Crawford, "A new focus on updating the tools currently used to assess the safety and efficacy of new medical products will very likely bring tremendous public health benefits." Because of its unique vantage point, the FDA can work with outside experts in companies, patient groups, and the academic community to coordinate, develop, and/or disseminate solutions to Critical Path problems, to improve the efficiency of product development industry-wide. Through this initiative, the FDA will take the lead in the development of a national Critical Path Opportunities List, to bring concrete focus to these tasks.
|
From page 389... ...
Available: http://www.fda.gov/oc/initiatives/ criticalpath/whitepaper.html · White Paper Executive Summary Available: http://www.fda.gov/ oc/initiatives/criticalpath/whitepaper.html#execsummary · Critical Path News Release Available: http://www.fda.gov/bbs/topics/news/2004/NEW01035.html
|
Key Terms
This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
More
information on Chapter Skim is available.